Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer
Main Authors: | Rea, D, Gray, R, Bowden, S, Handley, K, Earl, H, Poole, C, Bates, T, Dewar, J, Raytor, Z, Lee, M |
---|---|
Formato: | Conference item |
Publicado: |
2013
|
Títulos similares
-
Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study
por: Dennis C. Sgroi, et al.
Publicado: (2022-12-01) -
An Extraordinary New Toad (Bufo) ttom Costa Rica
por: Jay M Savage
Publicado: (2002-06-01) -
Tamoxifen-independent recombination in the RIP-CreER mouse.
por: Yanmei Liu, et al.
Publicado: (2010-10-01) -
Testing the untestable in language education /
por: Paran, Amos, et al.
Publicado: (c201) -
Association Between the Gut Microbiota and Blood Pressure in a Population Cohort of 6953 Individuals
por: Joonatan Palmu, et al.
Publicado: (2020-08-01)